Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/21/2026

Treatment of Hypercalcemia in Multiple Myeloma

Immediate Management

  • The National Comprehensive Cancer Network recommends treating hypercalcemia in multiple myeloma immediately with intravenous normal saline hydration followed by intravenous zoledronic acid 4 mg infused over no less than 15 minutes 1, 2
  • Administer intravenous normal saline promptly to correct hypovolemia and promote calciuresis, with a target urine output of 100-150 mL/hour 1, 3
  • Carefully assess fluid status to avoid hypervolemia, especially in patients with oliguria, cardiac failure, or renal impairment 1

Bisphosphonate Therapy

  • Zoledronic acid 4 mg IV infused over no less than 15 minutes is the treatment of choice, normalizing calcium levels in approximately 50% of patients by day 4 1, 2, 4
  • The maximum recommended dose is 4 mg; do not exceed this dose as renal toxicity increases with higher doses 1
  • Dosing adjustments for renal impairment are recommended, with a CrCl >60 mL/min: 4 mg, CrCl 50-60 mL/min: 3.5 mg, CrCl 40-49 mL/min: 3.3 mg, CrCl 30-39 mL/min: 3.0 mg 1

Alternative Agents

  • Denosumab is preferred over bisphosphonates in patients with renal disease, with a higher risk of hypocalcemia compared to bisphosphonates; monitor calcium closely 1, 5
  • Calcitonin provides rapid onset of action within hours but limited efficacy, and can be used as bridge therapy until bisphosphonates take effect 5, 4

Concurrent Supportive Measures

  • Administer oral calcium supplement 500 mg plus vitamin D 400 IU daily during bisphosphonate treatment, and correct pre-existing hypocalcemia before initiating bisphosphonate therapy 5
  • Avoid NSAIDs and intravenous contrast media in patients with renal impairment, and maintain hydration to decrease renal tubular light chain concentration 1, 2, 5

Critical Monitoring and Pitfalls

  • Perform baseline dental examination before starting bisphosphonates, and monitor for osteonecrosis of the jaw (ONJ); avoid invasive dental procedures during treatment 4
  • Monitor for hypocalcemia post-treatment, especially with denosumab, and treat only symptomatic hypocalcemia (tetany, seizures) with calcium gluconate 50-100 mg/kg 5, 4
  • Administer analgesia and bisphosphonates for painful bone lesions, and consider local radiotherapy (10-30 Gy) for uncontrolled pain, impending pathologic fracture, or spinal cord compression 2, 3

Treatment Indication for Hypercalcemia in Multiple Myeloma

Diagnostic Criteria

Guideline Recommendations

Definitive Disease Control

REFERENCES

1

nccn guidelines insights: multiple myeloma, version 1.2020. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

2

multiple myeloma, version 2.2016: clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2015

4

Tratamiento de Hipercalcemia en Linfoma No Hodgkin [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Treatment of Hypercalcemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025